Vyome Holdings (HIND) Current Deferred Revenue (2016 - 2026)
Vyome Holdings (HIND) posted quarterly Current Deferred Revenue of $24844.0 for Q1 2026, down 97.04% year-over-year from $838000.0 in Q1 2025, and down 4.76% quarter-over-quarter from $26086.0 in Q4 2025.
Vyome Holdings (HIND) Current Deferred Revenue (2016 - 2026) Analysis & Trends
Vyome Holdings' Current Deferred Revenue history runs 11 years deep, the most recent figure standing at $24844.0 for Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 97.04% year-over-year to $24844.0; the TTM figure through Mar 2026 stood at $24844.0 (down 97.04% YoY), while the FY2025 annual figure was $26086.0, down 96.38% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $24844.0, down from $26086.0 in the prior quarter.
- The five-year high for Current Deferred Revenue was $854000.0 in Q2 2025, with the low at $24844.0 in Q1 2026.
- The 5-year median for Current Deferred Revenue is $643000.0 (2024), against an average of $573262.0.
- The sharpest annual moves came in 2024 and 2026: Current Deferred Revenue surged 57.52% in 2024, then sank 97.04% in 2026.
- Vyome Holdings' Current Deferred Revenue stood at $510000.0 in 2022, then gained by 25.29% to $639000.0 in 2023, then grew by 12.68% to $720000.0 in 2024, then tumbled by 96.38% to $26086.0 in 2025, then declined by 4.76% to $24844.0 in 2026.
- Business Quant data shows HIND's Current Deferred Revenue at $24844.0 in Q1 2026, $26086.0 in Q4 2025, and $854000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Vyome Holdings | 16.07 Mn | 8.18 Mn | 11,658.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40,105.00 |
| Mar 31, 2026 | 24,844.00 |
| Dec 31, 2025 | 26,086.00 |
| Jun 30, 2025 | 854,000.00 |
| Mar 31, 2025 | 838,000.00 |
| Dec 31, 2024 | 720,000.00 |
| Sep 30, 2024 | 683,000.00 |
| Jun 30, 2024 | 723,000.00 |
| Mar 31, 2024 | 643,000.00 |
| Dec 31, 2023 | 639,000.00 |
| Sep 30, 2023 | 657,000.00 |
| Jun 30, 2023 | 459,000.00 |
| Mar 31, 2023 | 573,000.00 |
| Dec 31, 2022 | 510,000.00 |
| Sep 30, 2022 | 644,000.00 |
| Jun 30, 2022 | 605,000.00 |
| Dec 31, 2021 | 549,000.00 |
| Sep 30, 2021 | 580,000.00 |
| Jun 30, 2021 | 518,000.00 |
| Dec 31, 2020 | 398,000.00 |